Phoenix Biotech Acquisition Corp. (PBAX)
Price:
5.85 USD
( + 0.37 USD)
Your position:
0 USD
ACTION PANEL
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)

(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Apex Technology Acquisition Corporation
VALUE SCORE:
6
2nd position
M3-Brigade Acquisition V Corp. Units
VALUE SCORE:
11
The best
Horizon Kinetics SPAC Active ETF
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
No data to display
DESCRIPTION
Phoenix Biotech Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It engages in identifying and acquiring a business that focuses on the healthcare or healthcare related industries in the United States and Europe. The company was incorporated in 2021 and is based in Oakland, California.
NEWS

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination
businesswire.com
2024-02-14 16:48:00OAKLAND, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (“PBAX”) and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms (“CERo”) today announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company. In connection with the consummation of the business combinatio.
No data to display

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination
businesswire.com
2024-02-14 16:48:00OAKLAND, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (“PBAX”) and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms (“CERo”) today announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company. In connection with the consummation of the business combinatio.









